Research has indicated that tumor immune microenvironment and VEGF signaling pathway in HCC patients are synergistically activated, which suggests a prominent mechanism of combined therapy including immune checkpoint blockades (ICBs) and anti-VEGF drugs (Liu et al., 2020). Here, VEGFA is linked to hepatocellular carcinoma.